All In Biotech

Drug Trial Radar · NCT03471988

Clinical Study of AK1820 (Isavuconazonium Sulfate) for the Treatment of Deep Mycosis

A Phase 3, Multi-center, Open Label Study to Evaluate Safety and Efficacy of AK1820 for Treatment of Adult Japanese Patients With Deep Mycosis

Last checked: Nov 20, 2026Latest source record: May 14, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 103 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

103

Actual

Start

Apr 16, 2018

Primary completion

Apr 21, 2021

Study completion Apr 21, 2021

Sponsor

Sponsor type
Industry
First posted
Mar 21, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to investigate the safety and efficacy of administering 372.6 mg of AK1820 (isavuconazonium sulfate) intravenously or orally to adult Japanese patients with deep mycosis. The primary endpoint is safety (percentage of patients with adverse events after starting the study treatment).

Conditions

  • Deep Mycosis

Interventions

  • AK1820Drug

    Only a switch from IV infusion (vial) to oral administration (capsule) will be permitted; a switch from oral administration to IV infusion will not be possible. 372.6 mg of AK1820 (isavuconazonium sulfate) is equivalent to 200 mg of isavuconazole. Other Names: Cresemba, BAL8557

  • VoriconazoleDrug

    Only a switch from IV infusion (vial) to oral administration (tablet) will be permitted; a switch from oral administration to IV infusion will not be possible. Other Name : VFend

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of patients with adverse events between the first administration of investigational product and the end of Follow-up.Time frame: From the first study drug administration until 28 days after the last dose of study drug (up to approximately Day 112).

Locations

33 sites in 1 country. Site status is shown where the registry gives one.

  • Research site

    Chiba, Japan

  • Research site

    Ibaraki, Japan

  • Research site

    Nagasaki, Japan

  • Research site

    Nagakute, Aichi-ken, Japan

  • Research site

    Nagoya, Aichi-ken, Japan

  • Research site

    Seto, Aichi-ken, Japan

  • Research site

    Higashiku, Fukuoka, Japan

  • Research site

    Minamiku, Fukuoka, Japan

  • Research site

    Nagara, Gifu, Japan

  • Research site

    Naka-Ku, Hiroshima, Japan

  • Research site

    Asahikawa, Hokkaido, Japan

  • Research site

    Kawasaki, Kanagawa, Japan

  • Research site

    Yokohama, Kanagawa, Japan

  • Research site

    Chuo-Ku, Kumamoto, Japan

  • Research site

    Tsu, Mie-ken, Japan

  • Research site

    Isahaya, Nagasaki, Japan

  • Research site

    Ōmura, Nagasaki, Japan

  • Research site

    Sasebo, Nagasaki, Japan

  • Research site

    Tenri, Nara, Japan

  • Research site

    Yufu, Oita Prefecture, Japan

  • Research site

    Kurashiki, Okayama-ken, Japan

  • Research site

    Nakagami, Okinawa, Japan

  • Research site

    Abeno-Ku, Osaka, Japan

  • Research site

    Sakai, Osaka, Japan

  • Research site

    Ōmiya, Saitama, Japan

  • Research site

    Hamamatsu, Shizuoka, Japan

  • Research site

    Shimotsuke, Tochigi, Japan

  • Research site

    Kiyose, Tokyo, Japan

  • Research site

    Minato-Ku, Tokyo, Japan

  • Research site

    Mitaka, Tokyo, Japan

  • Research site

    Ōta-ku, Tokyo, Japan

  • Research site

    Shinagawa-Ku, Tokyo, Japan

  • Research site

    Shinjuku-Ku, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.